Novartis is trading 12.63% down at $139.79 after reporting that del-desiran failed to achieve its primary endpoint in the Phase III HARBOR study for myotonic dystrophy.
- Shares were indicated down about 5% pre-market; European trading later showed an 8.8% decline.
- The setback follows pelacarsen’s failed cardiovascular-outcomes trial, intensifying concerns about Novartis’s pipeline.
- The company reaffirmed its 2025–2030 sales-growth guidance.